TABLE 4.

TIGIT, CD226, and PD-1 expression from PBMC in MDS.

	Low Risk (N = 11)	High Risk (N = 15)	P	Significance
CD56+NK (%)	8.639 ± 6.443	3.982 ± 2.225	0.003	**
NK cells (cells/μL)	170.3 ± 99.24	142.7 ± 299.9	0.0043	**
TIGIT+NK (%)	18.77 ± 10.17	34.00 ± 15.35	0.0061	**
CD226+NK (%)	72.70 ± 10.28	55.65 ± 15.99	0.0057	**
CD3+T (%)	64.78 ± 8.526	44.40 ± 18.20	0.0013	**
T cells (cells/μL)	933.7 ± 383.9	660.2 ± 383.9	0.0170	*
TIGIT+T (%)	20.86 ± 9.387	39.49 ± 10.46	0.0001	***
CD226+T (%)	61.93 ± 11.73	49.31 ± 13.39	0.0221	*
PD-1+T (%)	19.56 ± 10.16	39.59 ± 13.42	0.0006	***
CD33+CD155 (%)	47.62 ± 26.32	67.65 ± 23.74	0.1480	NS
CD34+CD155 (%)	42.29 ± 27.15	77.94 ± 16.21	0.0433	*

MDS, myelodysplastic syndromes; PBMCs, peripheral blood mononuclear cell; *P < 0.05, **P < 0.01, ***P < 0.005; data are presented as mean ± SD using an unpaired t-test. The expression of TIGIT, CD226, and PD-1 were analyzed in MDS between low risk (N = 11) and high risk (N = 15).